Clinical associations between IL-17 family cytokines and periodontitis and potential differential roles for IL-17A and IL-17E in periodontal immunity by Azman R et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a  
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Azman R, Lappin DF, MacPherson A, Riggio M, Robertson D, Hodge P, 
Ramage G, Culshaw S, Preshaw PM, Taylor J, Nile C. Clinical associations 
between IL-17 family cytokines and periodontitis and potential differential 
roles for IL-17A and IL-17E in periodontal immunity. Inflammation Research 
2014, 63(12), 1001-1012. 
Copyright: 
The final publication is available at Springer via http://dx.doi.org/10.1007/s00011-014-0776-7 
Date deposited:   
02/12/2015 
  
Inflammation Research
 
IL-17 family cytokines in periodontitis
--Manuscript Draft--
 
Manuscript Number:
Full Title: IL-17 family cytokines in periodontitis
Article Type: Original Research Paper
Corresponding Author: Christopher John Nile, Ph.D
Infection and Immunity Research Group
Glasgow, UNITED KINGDOM
Corresponding Author Secondary
Information:
Corresponding Author's Institution: Infection and Immunity Research Group
Corresponding Author's Secondary
Institution:
First Author: Raja Azman Awang, BDS
First Author Secondary Information:
Order of Authors: Raja Azman Awang, BDS
David F Lappin, PhD
Alexandrea MacPherson, PhD
Marcello Riggio, PhD
Douglas Robertson, PhD
Penny Hodge, PhD
Gordon Ramage, Professor
Shauna Culshaw, PhD
Philip Preshaw, Professor
John Taylor, PhD
Christopher John Nile, Ph.D
Order of Authors Secondary Information:
Abstract: Objective: IL-17A is implicated periodontitis pathogenesis. The roles of IL-17B to IL-
17F are unknown. This study aimed to determine clinical associations between IL-17
family cytokines and periodontitis and to investigate the biological significance of IL-
17A and IL-17E using in vitro model systems.
Materials and Methods:  Serum, saliva and gingival crevicular fluid (GCF) levels of IL-
17 family cytokines were measured by ELISA. Oral keratinocytes were stimulated with
a P. gingivalis biofilm, or IL-17A, in the presence and absence of IL-17E and the
expression of IL-8 and CXCL5 were investigated by ELISA and real-time-PCR. NF-κB
phosphorylation in similar experiments was also measured using a cell-based ELISA.
Results: Serum, saliva and GCF IL-17A levels were higher in periodontitis patients and
correlated positively with clinical parameters of attachment loss, pocket depth and
bleeding on probing. Serum IL-17E levels were lower in periodontitis patients and the
serum IL-17A:IL-17E ratio correlated positively with clinical parameters. In vitro, IL-17E
inhibited P. gingivalis and IL-17A induced expression of chemokines by reducing
phosphorylation of the NF-κB p65 subunit.
Conclusions: Serum IL-17A:IL-17E may be a marker of disease severity. IL-17E may
have opposing roles to IL-17A in periodontitis pathogenesis. IL-17E can negatively
regulate IL-17A and perio-pathogen induced expression of chemokines.
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
Suggested Reviewers: Nurcan Buduneli, Professor
nurcan.buduneli@ege.edu.tr
Long standing history in research into the role of cytokines in the pathogenesis of
periodontitis
Sarah Gaffen, PhD
 sig65@pitt.edu
Expert in the filed of IL-17 family cytokine biology
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
1 
 
IL-17 family cytokines in periodontitis 
 
 
Raja Azman Awang
a
, David F Lappin
a
, Alexandrea MacPherson
a
, Marcello Riggio
a
, Douglas 
Robertson
a
, Penny Hodge
a 
, Gordon Ramage
a
, Shauna Culshaw
a
, Philip Preshaw
b
, John 
Taylor
b
, and Christopher Nile
a*
 
 
a
Infection and Immunity Research Group, Dental School, School of Medicine, College of 
Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK 
 
b
Centre for Oral Health Research and Institute of Cellular Medicine, Framlington Place, 
Newcastle University, Newcastle upon Tyne, England, NE2 4BW. 
 
 
*To whom correspondence should be addressed:  
 
Dr Christopher Nile 
Lecturer in Immunology 
Level 9 
University of Glasgow Dental School 
378 Sauchiehall Street 
Glasgow 
G2 3JZ 
Tel: + 44 (0) 141 211 9733 
Fax: +44 (0) 141 331 2798 
christopher.nile@glasgow.ac.uk 
 
 
 
 
 
 
 
 
Manuscript
Click here to download Manuscript: Final_manuscript.docx 
Click here to view linked References
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
2 
 
Abstract 
Objective: IL-17A is implicated periodontitis pathogenesis. The roles of IL-17B to IL-17F 
are unknown. This study aimed to determine clinical associations between IL-17 family 
cytokines and periodontitis and to investigate the biological significance of IL-17A and IL-
17E using in vitro model systems. 
 
Materials and Methods:  Serum, saliva and gingival crevicular fluid (GCF) levels of IL-17 
family cytokines were measured by ELISA. Oral keratinocytes were stimulated with a P. 
gingivalis biofilm, or IL-17A, in the presence and absence of IL-17E and the expression of 
IL-8 and CXCL5 were investigated by ELISA and real-time-PCR. NF-κB phosphorylation in 
similar experiments was also measured using a cell-based ELISA. 
 
Results: Serum, saliva and GCF IL-17A levels were higher in periodontitis patients and 
correlated positively with clinical parameters of attachment loss, pocket depth and bleeding 
on probing. Serum IL-17E levels were lower in periodontitis patients and the serum IL-
17A:IL-17E ratio correlated positively with clinical parameters. In vitro, IL-17E inhibited P. 
gingivalis and IL-17A induced expression of chemokines by reducing phosphorylation of the 
NF-κB p65 subunit. 
 
Conclusions: Serum IL-17A:IL-17E may be a marker of disease severity. IL-17E may have 
opposing roles to IL-17A in periodontitis pathogenesis. IL-17E can negatively regulate IL-
17A and perio-pathogen induced expression of chemokines. 
 
Keywords: IL-17, IL-25, IL-17E, IL-17A, Periodontitis, IL-8 
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1. Introduction 
The IL-17 family of cytokines consists of six members (IL-17A - IL-17F) [1]. IL-17A has 
been associated with periodontitis pathogenesis [2-6]. In vivo models suggest that IL-17A 
plays a protective role in periodontitis. Indeed, IL-17RA deficient mice show exacerbated 
bone loss in a Porphyromonas gingivalis induced model of periodontal disease [7]. However, 
an excessive IL-17A response promotes inflammatory alveolar bone loss in an ageing mouse 
model [8]. IL-17A signalling activates the receptor activator of nuclear factor kappa-B (NF-
κB), which in turn induces expression of a variety of pro-inflammatory mediators [9]. 
Furthermore, IL-17A can act  in synergy with TNF- and IL-1 and augment the expression 
of pro-inflammatory mediators from keratinocytes and fibroblasts [10-11]. Moreover, IL-17A 
can modulate bone remodelling through induction of RANKL both in vivo and in vitro [12-
13]. 
Like IL-17A, IL-17F can be secreted as a homodimer. However, a heterodimeric species 
consisting of a disulphide linked IL-17A and IL-17F molecule can also be formed [14]. 
Similarly to IL-17A, both the IL-17F homodimer and IL-17A/F heterodimer have pro-
inflammatory properties [15]. Elevated levels of IL-17F and IL-17A/F have been associated 
with chronic inflammatory diseases such as rheumatoid arthritis [13]. The biology of IL-17B, 
IL-17C and IL-17D are relatively poorly understood at present. Levels of IL-17B, IL-17C 
and IL-17D are elevated in inflammation driven pathologies, such as rheumatoid arthritis, and 
in vivo IL-17B, IL-17C and IL-17D can induce pro-inflammatory cytokine release from a 
variety of epithelial and myeloid cells [16]. Therefore, IL-17B, IL-17C, IL-17D, IL-17F and 
IL-17A/F appear to drive the pathogenesis of inflammatory diseases, but at present, their role 
in periodontitis pathogenesis remains unclear.  
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IL-17E has been described as a ‘double edged sword’ and has been shown to down-regulate 
localised destructive inflammation and promote Th2 driven pathologies [17], playing a major 
role in the clearance of parasitic infections [18] and the pathogenesis of allergic disease [19]. 
IL-17E induces activation and differentiation of Th2 cells and regulates their recruitment to 
sites of inflammation [20]. IL-17E also regulates Th9 cells [21] and activates multi-potent 
progenitor type 2 (MPP
type2
) cells, innate type 2 helper (Ih2) cells, natural helper cells 
(NHCs) and neuocytes [22]. In contrast, IL-17E down-regulates Th1/Th17 and IL-17A 
responses [23-25] and can directly inhibit toll-like receptor ligand driven expression of pro-
inflammatory cytokines via p38 MAP kinase-driven SOCS-3 activation in human blood 
monocytes and intestinal CD14
+
 cells [26-27]. Therefore, it is interesting to speculate that IL-
17E may play a role in down regulating potentially damaging localized inflammatory 
responses within the periodontium and protect against tissue destruction and alveolar bone 
loss.   
The aim of this study was to investigate the relationships between all IL-17 family cytokines 
and periodontitis, by investigating serum, saliva and GCF levels of IL-17A - IL-17F and the 
IL-17A/F heterodimer in patients with periodontitis and periodontally healthy controls. In 
addition, we sought to investigate whether IL-17A and IL-17E might have opposing roles in 
periodontal innate immunity.  Therefore, the ability of IL-17E to inhibit IL-17A and P. 
gingivalis induced expression of the neutrophil chemoattractant chemokines (IL-8 and 
CXCL5), via differential activation of the NF-κB transcription factor, was investigated.  
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2. Materials and Methods 
2.1 Ethics and sample collection 
Samples were selected from independent studies conducted at Glasgow and Newcastle and 
were from patients with periodontitis or healthy controls that were systemically healthy non 
smokers. The sample collection and ethical approvals for the Glasgow sample cohort were as 
previously described [28]. The sample collection and ethical approvals for the Newcastle 
cohort are as previously described [29-31]. All samples were collected by similar methods in 
the two centres except for saliva. Therefore, saliva data was analysed separately. 
 
2.2 Enzyme-linked immunosorbent assays (ELISA) 
IL-17A – IL-17F and IL-17A/F were assayed using commercially available ELISA kits, 
according to the manufacturer’s instructions. IL-17D was assayed using an optimised ELISA 
developed with 2 μg/ml rabbit anti-human IL-17D capture antibody (Peprotech, UK) and 0.5 
μg/ml biotinylated anti-human IL-17D detection antibody (Peprotech, UK). CXCL5 (ENA-
78) and CXCL8 (IL-8) concentrations were investigated by ELISA (CXCL5/ENA-78 Duoset, 
R&D Systems, UK and IL-8 Cytoset, Invitrogen, UK). The limits of detection were 
determined as two mean standard deviations higher than the mean baseline from 6 replicate 
standard curves: IL-17A = 1.9 pg/ml, IL-17B = 7.8 pg/ml, IL-17C = 7.8 pg/ml, IL-17D = 9.8 
pg/ml, IL-17E = 1.9 pg/ml, IL17-F = 1.9 pg/ml, IL-17A/F = 2.5 pg/ml, IL-8 = 1.6 pg/ml and 
CXCL5 = 3.9 pg/ml. 
2.3 Porphyromonas gingivalis biofilms  
P. gingivalis ATCC 33277 was cultured under anaerobic conditions at 37 
o
C in Schaedler 
anaerobe broth (Oxoid, UK) for 2 days. The bacteria were then washed by centrifugation in 
PBS and standardised to 1 x 10
7
 cells/ml in artificial saliva (AS) [32]. 500 l of P. gingivalis 
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suspension was cultured on Thermanox
®
 plastic coverslips (NUNC, UK) at 37 
o
C in an 
anaerobic environment for 4 days, with AS replaced daily. After incubation, the non-adherent 
cells were removed and the biofilms were kept at -80 
o
C prior to use. 
 
2.4 In vitro experiments  
OKF6/TERT-2 oral keratinocytes were a gift from the Rheinwald laboratory (Brigham and 
Women’s Hospital, Boston). OKF6/TERT-2 cells were cultured as previously described [33]. 
P. gingivalis ATCC 33277 biofilms were used in co-culture experiments with epithelial cells 
as described previously [34], with varying concentrations of IL-17E (Peprotech, UK). Un-
stimulated cells and cells stimulated with IL-17E alone were used as controls.   
 
The effect of IL-17E on IL-17A induced IL-8 expression was determined by stimulating 
OKF6/TERT-2 cells concomitantly with IL-17A (Peprotech, UK) alone or in combination 
with IL-17E (Peprtoech, UK) for 24 h. In addition, cells were pre-incubated for 30 min with 
IL-17E, prior to stimulation with IL-17A. Un-stimulated cells and cells stimulated with IL-
17A and IL-17E alone were used as controls.   
 
2.5 Real time PCR analysis 
mRNA was isolated using the RNeasy
®
 Kit (Qiagen, UK), and reverse transcribed using the 
High Capacity RNA-to-cDNA Master Mix (Applied Biosystem, UK), according to the 
manufacturer’s instructions. IL-8 and CXCL5 mRNA expression was analysed using SYBR® 
green Real Time PCR with the following primers, GAPDH: Fwd: 
CAAGGCTGAGAACGGAAG and Rev: GGTGGTGAAGACGCCAGT, IL-8: Fwd: 
CAGAGACAGCAGAGCACACAA and Rev: TTAGCACTCCTTGGCAAAAC and 
CXCL5: Fwd: CCCTGGGTTCAGAGACCTCCA and Rev: 
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CCAGAAAATTTTGGACGGTGGAAACA. Relative expression of IL-8 and CXCL5 
mRNA was calculated using the 2
-CT
 method [35]. 
2.6 Fast Activated Cell-based ELISA (FACE
TM
) NF-κB p65 Profiler 
Phosphorylation profiles of the NF-κB p65 subunit was investigated using the FACETM NF-
κB p65 Profiler (Active Motif, UK) in accordance with manufacturer’s instructions. The % of 
the total NF-κB p65 subunit phosphorylated at serine 468 or serine 536 was calculated in 
accordance with the manufacturer’s instructions. 
 
2.7 Statistical analyses 
All statistical analyses were carried out using SPSS (Version 18). Serum and GCF samples 
from Glasgow and Newcastle were originally analysed separately and similar results 
observed. To increase statistical power, data from the 2 patient cohorts were combined; with 
the exception of the data from analysis of saliva samples.  
 
Statistical power exceeded 80 % when n= ≥29 utilizing a fixed effect size of 1 and the 
assumption of normally distributed data. Q-Q plot analysis showed the data was not normally 
distributed. Therefore group sizes were increased to ≥34.  For the majority of analyses, 
sufficient statistical power was achieved. However, due to limitations in sample volume, 
some analyses were underpowered and therefore described as exploratory in nature.  
 
The Mann-Whitney-U test and Bonferroni correction was used to determine significant 
differences between health and disease.  Due to a significant age difference between the two 
groups (Table 1) adjustments were performed using a weighted t-test analysis of the natural 
log (Ln) transformed data.   
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Bivariate correlations were performed using Spearman rho serum and GCF samples. 
However, due to the limited number of saliva samples from the Newcastle cohort only the 
Glasgow saliva samples were analysed in this respect. A Pearson correlation of Ln 
transformed data was used to adjust for differences in age. Serum IL-17A:IL-17E ratios were 
subjected to Ln transformations to facilitate graphical representation.  
 
Statistical analysis of chemokine ELISA data was performed by Ln transformation followed 
by an ANOVA with a post hoc Bonferroni correction. Real time PCR data was analysed by 
performing a Levenes’s test on the Ln transformed  2-∆CT values followed by an independent 
t-test to compare two means [35]. 
 
Fast Activated Cell-based ELISA (FACE
TM
) NF-κB p65 Profiler data was transformed and 
analysed with a Holm-Bonferroni corrected t-test.  
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3. Results 
3.1 Clinical parameters  
77 healthy volunteers (62 Glasgow; 15 Newcastle) and 97 patients with periodontitis (71 
Glasgow; 26 Newcastle) were enrolled in the study. The median age of the healthy subjects in 
the Glasgow study was significantly lower than periodontitis patients (Table 1A), but patients 
and controls were of similar age in the Newcastle study (Table 1B). Commensurate with 
periodontal health, the healthy subjects in both studies had significantly lower median % of 
sites that bled on probing (BOP), lower median clinical probing depth (CPD) and lower 
clinical attachment loss (CAL) compared to patients with periodontitis (Table 1A and B). 
Table 1C shows that in the combined cohort the median age, the median BOP, the median 
CPD and the median CAL were all significantly lower for healthy volunteers than 
periodontitis patients. 
3.2 Serum, gingival crevicular fluid and saliva levels of IL-17 family cytokines  
Circulating median concentration levels of IL-17A and IL-17A/F were greater in patients 
with periodontitis compared to healthy volunteers (Table 2A). There were significantly lower 
circulating levels of IL-17E in periodontitis patients compared to healthy volunteers. 
Weighted analyses of transformed data confirmed that none of these differences were due to 
differences in age of participants. There were no significant differences in circulating median 
concentrations of IL-17B, C, or D between healthy volunteers and periodontitis patients; 
irrespective of correction for age. 
 
Due to limitations of sample volume, GCF analysis was restricted to IL-17A, IL-17E, IL-17F 
and IL-17A/F. The median total amounts of IL-17A, IL-17F and IL-17A/F in GCF was 
elevated in patients with periodontitis (Table 2B). However, there was no significant 
difference in amounts of IL-17E. Weighted analysis of transformed data confirmed that these 
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findings were not due to differences in age of the participants. The findings for IL-17F and 
IL-17A/F can only be interpreted as exploratory due to insufficient power.  
 
Saliva samples from Glasgow and Newcastle were analysed in isolation due to differences in 
collection methodology (Table 2C and Table 2D). Only IL-17A, IL-17E, IL-17F and IL-
17A/F were measured due to limitations in sample volume. In the Glasgow cohort salivary 
levels of IL-17A, IL-17E, IL-17F and the IL-17A/F heterodimer were greater in periodontitis 
patients than healthy controls. Weighted analysis of transformed data confirmed these 
findings were not due to age differences. Analysis of the Newcastle samples also revealed 
elevated salivary levels of IL-17A and IL-17A/F in periodontitis patients compared to healthy 
controls. In contrast, there were no significant differences in levels of IL-17E and IL-17F. 
These findings can only be interpreted as exploratory due to insufficient power.  
 
 
The IL-17A:IL-17E ratio was calculated for serum, GCF and saliva of each participant (Table 
2E). The IL-17A:IL-17E ratio was significantly higher in serum of periodontitis patients than 
healthy controls (p<0.0001), but not in GCF or saliva. This was confirmed not to be 
influenced by differences in the age of the participants using a weighted analysis. 
 
3.3 Associations between IL-17 family cytokines, clinical parameters and demographics  
Table 3 shows correlations between serum, saliva (Glasgow only) and GCF levels of IL-17A, 
IL-17E, IL-17F and IL-17A/F and clinical parameters as well as age. Serum concentrations of 
IL-17A demonstrated a significant positive correlation with age, PD, CAL and BOP.  In 
contrast, serum concentrations of IL-17E showed a significant negative correlation with PD 
and CAL, but not with age or BOP. Partial bivariate correlation analysis demonstrated that 
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after correction for age, significantly stronger negative correlations were seen for IL-17E 
with PD (R=-0.275, p=0.0021) and CAL (R=-0.317, p=0.0007). Circulating levels of IL-17E 
negatively correlated with IL-17A (rho=-0.194, p=0.041). Again, adjustment for age resulted 
in a stronger correlation (R=-0.580, p=<0.0001). Serum levels of IL-17A/F showed 
significant positive correlations with age, PD, CAL and BOP, both before and after correction 
for age.  
 
GCF levels of IL-17A correlated significantly with age, PD, CAL and BOP. In addition, GCF 
levels of IL-17E showed a significant positive correlation with PD, CAL and BOP, but not 
with age. Furthermore, GCF levels of IL-17F and IL-17A/F correlated with age, PD, CAL 
and BOP. Partial correlation analysis confirmed that these correlations were not influenced 
by age.  
 
Due to the limited number of saliva samples from the Newcastle cohort, correlation analysis 
was only performed on the Glasgow samples. Salivary levels of IL-17A significantly 
correlated with age, PD, and CAL, but not with BOP. In addition, salivary levels of IL-17E 
showed significant positive correlations with age, PD, CAL and BOP. Salivary IL-17F 
concentrations also correlated significantly with age, PD and CAL, but not with BOP and 
salivary levels of IL-17A/F only correlated significantly with age. Partial bivariate correlation 
analysis confirmed that these correlations were not influenced by age.  
 
3.4 Correlations between serum IL-17A/IL-17E ratio and clinical parameters 
Circulating levels of IL-A negatively correlated with levels of IL-17E (R=-0.323, p=0.0006). 
The serum IL-17A:IL-17E ratio was significantly elevated in patients with periodontitis 
compared to healthy volunteers (Table 2E), suggesting the ratio may be a marker of disease. 
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The serum IL-17A:IL-17E exhibited moderate/strong correlations with CAL, PD and a weak 
correlation with BOP. Partial correlation analyses confirmed these findings were not 
influenced by the subject’s age. 
 
3.5 IL-17E inhibits the IL-17A induced release of IL-8 from oral keratinocytes 
Stimulation of OKF6/TERT-2 cells with IL-17A alone for 24 h induced significant release of 
IL-8 compared to unstimulated control cells (P=<0.01, Figure 2A). In contrast, stimulation 
with IL-17E alone had no effect. There was a dose-dependent decrease in IL-17A-induced 
IL-8 release from OKF6/TERT-2 cells when stimulated concomitantly with varying 
concentrations of IL-17E, which was significant only with 400 ng/ml IL-17E  (p<0.01). 
Thirty minutes of pre-incubation with IL-17E resulted in greater inhibition of IL-17A-
induced IL-8 release. Once again, there was a dose-dependent decrease in IL-17A-induced 
IL-8 release from OKF6/TERT-2 cells. However, on this occasion the inhibition was 
significant with 10, 50, 100, 200 and 400 ng/ml IL-17E (Figure 2B). The inhibitory effect of 
IL-17E was mediated at the transcriptional level. Stimulation of OKF6/TERT-2 cells with 10 
ng/ml IL-17A alone induced a significant 7-fold increase in IL-8 mRNA expression 
(p=<0.01, Figure 2C). Furthermore, 30 minute pre-stimulation with 10 and 50 ng/ml IL-17E 
reduced the IL-17A induced up-regulation of IL-8 mRNA expression. However, this 
reduction was only significant with 50 ng/ml IL-17E (p=<0.01, Figure 2C). 
 
3.6 IL-17E inhibits the IL-17A induced activation of NFB in epithelial cells 
Exposure of OKF6/TERT-2 cells to 10 ng/ml IL-17A or 50 ng/ml IL-17E alone (or in 
combination) had no significant effect on total NF-κB p65 subunit levels compared to 
unstimulated control cells (data not shown).  
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Stimulation of OKF6/TERT-2 cells with 10 ng/ml IL-17A caused significantly elevated 
phosphorylation of the NF-κB p65 subunit at serine 468 and 536 (p<0.05) compared to 
unstimulated control cells. Addition of 50 ng/ml IL-17E to cultures 30 minutes prior to 
addition of IL-17A significantly decreased IL-17A-induced NF-κB P65 serine 468 and 536 
phosphorylation (p<0.05, Figure 3A and B).  
 
3.7 IL-17E inhibits the Porphyromonas gingivalis induced release of chemokines from oral 
keratinocytes 
Stimulation of OKF6/TERT-2 cells with a live P. gingivalis biofilm for 4 h and 24 h induced 
a significant increase in IL-8 mRNA expression (p<0.05) compared to unstimulated control 
cells, which was inhibited by 50 ng/ml IL-17E (p<0.05, Figure 4A). These changes in mRNA 
expression were mirrored by changes in protein expression. P. gingivalis significantly 
elevated release of IL-8 after 4 h and 24 h (p<0.05), and this was significantly inhibited by 50 
ng/ml IL-17E at 24 h (p<0.05, Figure 4B). 
 
Stimulation of OKF6-TERT2 cells with a live P. gingivalis biofilm for 4 h and 24h induced a 
significant increase in CXCL5 mRNA expression (P<0.05) compared to unstimulated control 
cells, which was inhibited by 50 ng/ml IL-17E (P<0.05, Figure 4C). These changes in mRNA 
expression were mirrored by changes in protein expression. The P. gingivalis-induced 
CXCL5 release was inhibited by 50 ng/ml IL-17E at 4h and 24 h (P=<0.05) (Figure 4D).  
 
None of the observed effects were related to cell viability as determined by a lactate 
dehydrogenase (LDH) activity assay (data not shown).  
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4. Discussion 
This study further advances understanding of IL-17 family cytokines in periodontitis, with 
the novel observation of a significant increase in serum levels of the IL-17A/F heterodimer in 
periodontitis patients which correlated with clinical parameters. In agreement with previous 
studies these findings confirm that serum, saliva, and GCF levels of IL-17A are elevated in 
periodontitis patients and correlate with clinical parameters of periodontitis and age [2-6]. In 
addition, serum levels of the IL-17A/F heterodimer positively correlated with serum levels of 
both IL-17A and IL-17F. There were no significant differences in serum IL-17F, IL-17B, IL-
17C and IL-17D levels between periodontitis patients and healthy controls. Periodontitis 
patients presented with decreased serum levels of IL-17E, which negatively correlated with 
PD and CAL and serum IL-17A. The negative correlation between serum levels of IL-17A 
and IL-17E is particularly interesting given the proposed opposing immunological functions 
of these cytokines. Indeed, the findings presented suggest that the circulating IL-17A:IL-17E 
ratio may be a marker of disease as it showed moderate-good correlations with CAL and PD. 
 
This study has demonstrated further novel findings with regards to GCF and salivary levels of 
IL-17A, IL-17E, IL-17F and IL-17A/F and associations between levels of these individual 
cytokines as well as clinical parameters of periodontitis. In addition, the studies show that 
relationships between these cytokines and clinical parameters differ depending on the bodily 
fluids investigated. Indeed, in contrast to the serum analysis, the exploratory investigations 
revealed that the GCF and salivary IL-17A:IL-17E ratio was not significantly increased in 
periodontitis patients. This was possibly because GCF and salivary levels of IL-17E were in 
fact elevated in patients with periodontitis. Differences in levels of IL-17 family cytokines in 
serum, saliva and GCF could possibly be explained by the anatomical location from which 
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these biological fluids are derived [36]. However, this is a matter of conjecture until we have 
a complete picture of IL-17 family cytokine biology. 
 
GCF levels of IL-17A in patients with periodontitis [2] and serum levels of IL-17A in 
patients with aggressive periodontitis [3] have been shown to be reduced after non-surgical 
therapies. In addition, there is also evidence of Th17 cells in the periodontium [37-38]. IL-
17A promotes recruitment of neutrophils and monocytes by inducing chemokine expression 
[39], commensurate with the data in our current study demonstrating that IL-17A induced 
oral keratinocytes to express IL-8. This was in contrast to IL-17E which alone had no effect 
on IL-8 expression. However, IL-17E was found to inhibit the IL-17A-induced expression of 
IL-8 by oral keratinocytes. This inhibition was more pronounced if IL-17E was added to cells 
30 minutes prior to IL-17A. The notable inhibition of IL-17A induced IL-8 following pre-
incubation with IL-17E suggests that IL-17E induces intracellular signalling events that 
mediate IL-17A induced IL-8 transcription. Hence, we therefore investigated NF-κB. IL-17A 
was shown to promote IL-8 expression via intracellular signalling pathways leading to the 
phosphorylation of the NF-κB p65 subunit at serine 536 and serine 468. Phosphorylation of 
serine 536 of the NF-κB p65 subunit has been demonstrated to be important in transcription 
of the IL-8 gene [40], while phosphorylation at serine 468 has been shown to have an 
important role for NF-κB ubiquitination and degradation [41]. However, despite their 
opposing functions, phosphorylation at serine 536 and 468 occurs simultaneously [42]. In this 
study, IL-17E inhibited the IL-17A induced phosphorylation events which promote NF-κB 
p65 subunit activation. This suggests that IL-17E inhibition of IL-8 expression is regulated at 
the transcriptional level by intracellular signalling pathways which inhibit activation of the 
NF-κB transcription factor. However, further studies are required to delineate which 
pathways are responsible.  
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IL-17E has been shown to regulate the innate immune responses of bacterial LPS stimulated 
myeloid cells [27]. Our studies show that a similar phenomenon occurs in oral keratinocytes. 
P. gingivalis up-regulated the expression of IL-8 and CXCL5 in accordance with previous 
studies [43-44]. However, IL-17E inhibited the P. gingivalis induced expression of both these 
chemokines and this inhibition was evident at the mRNA level. Increased expression of IL-
17E occurs only in later stages of disease in a collagen-induced arthritis mouse model [69], 
which may explain the paradoxical findings between the serum and salivary and GCF levels 
of IL-17E. Compared with serum, GCF and to some extent saliva may provide a more 
representative picture of the events occurring within diseased periodontal tissue. Therefore 
based on the findings in this manuscript, and the current literature, it could be argued that 
increased expression of IL-17E in periodontal tissue occurs as an attempt to down-regulate 
the damaging localised periodontal inflammatory response.  
 
In conclusion, these data confirm that IL-17 family cytokines play a role in periodontitis. 
Interestingly, the data suggests that IL-17A and IL-17E may have opposing functions in 
disease pathogenesis and that the serum IL-17A:IL-17E ratio may be a marker of disease 
severity. Furthermore, these data suggest that IL-17E down-regulates both IL-17A and P. 
gingivalis-induced expression of chemokines by oral keratinocytes. The cellular sources and 
exact signalling mechanisms of most IL-17 family cytokines in the periodontium remain to 
be characterised hence further research is required to fully delineate the biological functions 
of these cytokines and their role in periodontitis.  
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Figure legends 
 
 
Fig. 1  
 
Correlations between the serum IL-17A:IL-17E ratio and clinical and demographic 
parameters. Serum IL-17A:IL-17E ratios were subjected to natural log transformations to 
facilitate graphical representation of the correlations between (A) Clinical attachment loss 
(CAL), (B) Probing depth, (C) bleeding on probing (BOP) and (D) age. The Pearson 
correlation coefficient was determined (R). All were statistically significant correlations 
(p<0.010).  
 
 
Fig. 2  
The effect of IL-17E on IL-17A induced IL-8 expression by OKF6/TERT-2 cells. (A) Mean 
± standard deviation IL-8 release from OKF6/TERT-2 cells stimulated concomitantly with 
combinations of IL-17A and IL-17E (see x axis for concentrations) (n=3). Statistical analysis 
was performed by log transforming the data followed by an ANOVA with a post hoc 
Bonferroni correction (**p<0.01). (B) Mean ± standard deviation IL-8 release from 
OKF6/TERT-2 cells pre-incubated with IL-17E for 30 min prior to stimulation with IL-17A 
(see x axis for concentrations) (n=3). Statistical analysis was performed by log transforming 
the data followed by an ANOVA with a post hoc Bonferroni correction (*p=<0.05, 
**p<0.01). (C) Fold induction change (± standard deviation) in IL-8 mRNA expression by 
OKF6/TERT-2 cells pre-incubated with IL-17E for 30 min prior to stimulation with IL-17A 
(see x axis for concentrations) (n=3). Statistical analysis of real time PCR data was performed 
by a Levenes’s test of homoscedasticity on the natural log transformed 2-∆CT values followed 
by an independent t-test to compare two means  (**p=<0.01). ± =statistical significance in 
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comparison to un-stimulated control, # = statistical significance in comparison to cells 
stimulated with 10 ng/ml IL-17A only.  
 
Fig. 3  
The effect of IL-17E on IL-17A induced phosphorylation of the NF-κB p65 subunit at serine 
468 and serine 536 by OKF6/TERT-2 cells. (A) Mean (± standard deviation) angular 
transformed % of NF-κB p65 subunit phosphorylated at serine 468 pre-incubated with IL-
17E for 30 min prior to stimulation with IL-17A (see x axis for concentrations) (n=3). (B) 
Mean (± standard deviation) angular transformed % of NF-κB p65 subunit phosphorylated at 
serine 536 pre-incubated with IL-17E for 30 min prior to stimulation with IL-17A (see x axis 
for concentrations) (n=3). Statistical analysis was performed by ANOVA and a post hoc 
Holm-Bonferroni (H-B) corrected least significant difference test (*p<0.05/H-B). ± = 
statistical significance in comparison to un-stimulated control, # = statistical significance in 
comparison to cells stimulated with 10 ng/ml IL-17A only.  
 
Fig. 4 
The effect of IL-17E on P. gingivalis biofilm induced IL-8 expression by OKF6/TERT-2 
cells The data shows the effect of P. gingivalis alone, IL-17E alone or IL-17E (50 ng/ml; 
added 30 minutes prior) in combination with a P. gingivalis biofilm on the expression of IL-8 
at the mRNA (A) and protein level (B) and CXCL5 at the mRNA (C) and protein (D) level. 
Changes in mRNA expression were determined by real time PCR and protein release by 
ELISA. For the real time data mRNA levels were normalised against GAPDH (housekeeping 
gene) and fold induction calculated by the 2
-CT 
method. Each bar represents the mean (± 
standard deviation). For the ELISA data, each bar represents the mean (± standard deviation). 
All data is derived from duplicate wells of four independent experiments performed on 
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separate days (n=4). *P < 0.05. Ns = not significant. ± = statistical significance in comparison 
to un-stimulated control, # = statistical significance in comparison to cells stimulated with P. 
gingivalis biofilm only.  
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Figure 4
Table 1. Demographic and clinical data for the sample cohorts 
   
A. Glasgow Healthy (n=62; 44% M ) Periodontitis (n=71; 49% M) 
AGE 34 (26 – 44) 47 (41 – 53) 
  36 ± 11 47 ± 8 
     
% BOP 2.7 (0.0 - 9.0) 36.3 (23.5 -44.7) 
  8.2 ± 11.9 35.3 ± 20.7 
     
CPD 1.34 (1.00 - 1.69) 2.83 (2.69 - 3.11) 
  1.54 ± 0.50 2.92 ± 0.63 
     
CAL  < 2mm
a
 3.45 (3.03 - 3.94) 
    3.66  ± 0.89 
   
B. Newcastle Healthy (n=15; 69% M ) Periodontitis (n=26; 31% M) 
AGE 47 (42 – 54) 48 (46 – 54) 
  49 ± 8 50 ± 6 
     
% BOP 0.6 (0.0 – 2.1) 39.9 (29.2 – 51.9) 
  1.1 ± 1.1 43.0 ± 20.6 
     
CPD 1.48 (1.21 - 1.69) 2.87 (2.69 - 3.27) 
  1.58 ± 0.12 3.67 ± 1.10 
     
CAL  < 2mm
a
 3.33 (3.03 - 3.94) 
    3.12  ± 0.77 
   
C. Combined Healthy (n=77; 56.5% M ) Periodontitis (n=97; 40.0% M) 
AGE 38 (27 – 49) 47 (42 – 53) 
  38 ± 12 47 ± 8 
     
% BOP 2.7 (0.0 - 9.0) 36.0 (25.0 - 48.8) 
  6.7 ± 11.0 38.8 ± 20.8 
     
CPD 1.48 (1.21 - 1.69) 2.87 (2.69 - 3.27) 
  1.51 ± 0.48 3.10 ± 0.83 
     
CAL  < 2mm
a
 3.33 (3.03 - 3.94) 
    3.53  ± 0.89 
BOP = Bleeding on probing 
CPD = Clinical probing depth 
CAL = Clinical attachment loss (
a
could not accurately be determined in the healthy group) 
Significant differences between health and periodontitis groups shown in bold (p<0.01)  
Median values shown with inter-quartile range in brackets and mean ± standard deviation underneath 
Table 1
Table 2. IL-17 family cytokine levels and the IL-17A:IL-17E ratio in serum, gingival 
crevicular fluid and saliva 
 
A       
Serum (pg/ml) Healthy n=  Periodontitis n=  
IL-17A 15.5 (5.3 - 30.1)* 77  47.5 (38.7 - 98.0)* 97  
IL-17B 38.8 (30.8 - 48.1) 40  33.8 (18.2 - 59.3) 55  
IL-17C 40.9 (2.9 - 49.8) 40  31.6 (12.0 - 51.7) 55  
IL-17D 22.1 (20.1 - 30.6) 38  23.8 (21.0 - 28.8) 41  
IL-17E 35.3 (23.1 - 44.0)* 77  17.2 (15.9 - 50.3)* 97  
IL-17F 14.3 (4.0 - 32.2) 77  14.2 (7.2 - 20.0) 97  
IL-17A/F 8.0 (0.0 - 26.0)* 77  31.4 (24.8 - 53.7)* 97  
       
B       
GCF (pg) Healthy n=  Periodontitis n=  
IL-17A 44.4 ( 5.0 - 117.2)* 37  94.9 ( 76.6 - 119.6)* 41  
IL-17E 53.5 ( 2.0 - 85.9) 37  70.6 ( 42.2 - 128.8) 41  
IL-17F 3.9 ( 1.9 - 7.8)* 21  6.4 ( 5.8 - 12.5)* 13  
IL-17A/F 5.5 ( 4.9 - 15.0)* 21  19.0 ( 15.0 - 35.0)* 13  
       
C       
Saliva (pg/ml) 
Glasgow 
Healthy n= 
 
Periodontitis n= 
 
IL-17A  9.8 (8.0 - 15.9) * 24  17.8 (10.7 - 28.4)* 38  
IL-17E  5.3 (3.9 - 17.5) * 24   51.7 (25.1 - 128.5)* 38  
IL-17F 3.9 (1.9 - 7.8)* 24  11.2 (6.6 - 19.3)* 38  
IL-17A/F 12.6 (4.4 - 15.1) * 24  29.3 (24.4 - 47.8)* 38  
       
D       
Saliva (pg/ml) 
Newcastle 
Healthy n= 
 
Periodontitis n= 
 
IL-17A 16.9 (10.2 - 25.2) * 13  48.3 (21.7 - 130.4)* 26  
IL-17E 46.8 (38.9 - 92.9)  13  57.5 (30.0 - 100.1) 26  
IL-17F 10.0 (8.5 - 13.6)  13  9.5 (8.0 - 16.3) 26  
IL-17A/F 31.1 (23.5 - 37.8)* 13  46.8 (38.9 - 92.9) *  26  
       
E       
IL-17A:IL-17E Healthy  n=  Periodontitis  n=  
Serum 0.48 (0.10 - 0.98)* 77  2.62 (0.82 - 4.47)* 97  
GCF 0.50 (0.21 - 2.43) 37  0.59 (0.16 - 1.49) 41  
Saliva 0.75 (0.30 - 1.28) 37  0.82 (0.50 - 1.07) 64  
*Significant differences (p<0.050) between health and periodontitis groups shown in bold 
Median values shown with inter-quartile range in brackets  
Table 2
Table 3. Correlations between clinical and demographic parameters and levels of IL-17A, IL-
17E, IL-17F and IL-17A/F in serum, gingival crevicular fluid and saliva 
A      
Serum  AGE PD CAL %BOP 
 
IL-17A rho=  0.338 0.429 0.464 0.331 
 p= 0.00001 0.00001 0.00001 0.00001 
IL-17E rho= 0.031 -0.265 -0.291 -0.060 
 p= 0.68444 0.00029 0.00010 0.43266 
IL-17F rho=  -0.080 -0.025 -0.002 0.024 
 p= 0.30314 0.74575 0.97826 0.75304 
IL-17A/F rho=  0.598 0.544 0.436 0.375 
 p= 0.00001 0.00001 0.00001 0.00001 
      
B      
GCF  AGE PD CAL %BOP 
 
IL-17A rho= 0.484 0.611 0.543 0.273 
 p= 0.00001 0.00001 0.00001 0.01620 
IL-17E rho= 0.217 0.415 0.463 0.355 
 p= 0.05853 0.00017 0.00002 0.00153 
IL-17F rho= 0.481 0.449 0.469 0.349 
 p= 0.00397 0.00777 0.00517 0.04325 
IL-17A/F rho= 0.531 0.435 0.444 0.368 
 p= 0.00125 0.01005 0.00845 0.03228 
     
C     
Saliva (Glasgow only)  AGE PD CAL %BOP 
 
IL-17A rho= 0.385 0.585 0.520 0.275 
 p= 0.0239 0.00001 0.00193 0.11485 
IL-17E rho= 0.5999 0.673 0.761 0.480 
 p= 0.00019 0.00001 0.00001 0.00407 
IL-17F rho= 0.405 0.462 0.404 0.2536 
 p= 0.01855 0.01145 0.0199 0.16671 
IL-17A/F rho= 0.485 0.199 0.212 0.050 
 p= 0.00509 0.55480 0.45691 0.85645 
Significant correlations shown in bold (p<0.050)  
Bivariate correlations performed using Spearmans rho 
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